NCT04495790Recruiting
AIMS Cancer Outcomes Study
Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study
Source: ClinicalTrials.gov · Last updated 1 Feb 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 29 Jul 2020
- Start date
- 18 May 2020
- Primary completion date
- 18 May 2025
- Lead sponsor
- Advanced Integrative Medical Science Institute
- Diseases
- Childhood cancers
- NCT number
- NCT04495790
What you commit to
- Study type: Observational
- Planned participants: 500
- From 18 May 2020 to the primary completion date, 18 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients not diagnosed with cancer;
Other
- Telehealth patients;
- Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
- Unwilling to participate in the AIMS Institute observational study.
Who the study is looking for
- A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
- An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
- If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
- If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
- A confirmed diagnosis of cancer based on medical oncology medical records.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AIMS Institute Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.